Phillip Md Et Al Frost Buys 100,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock in a transaction that occurred on Thursday, November 14th. The shares were purchased at an average cost of $1.62 per share, for a total transaction of $162,000.00. Following the purchase, the chief executive officer now directly owns 211,612,405 shares of the company’s stock, valued at approximately $342,812,096.10. This trade represents a 0.05 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 8th, Phillip Md Et Al Frost purchased 280,183 shares of OPKO Health stock. The stock was acquired at an average price of $1.50 per share, with a total value of $420,274.50.

OPKO Health Stock Up 1.2 %

Shares of NASDAQ:OPK opened at $1.64 on Friday. The stock has a 50-day simple moving average of $1.52 and a 200-day simple moving average of $1.43. The stock has a market capitalization of $1.12 billion, a P/E ratio of -8.63 and a beta of 1.65. OPKO Health, Inc. has a 1 year low of $0.85 and a 1 year high of $1.75. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97.

Institutional Investors Weigh In On OPKO Health

Several large investors have recently made changes to their positions in OPK. CIBC Asset Management Inc lifted its position in OPKO Health by 79.1% during the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 8,978 shares in the last quarter. FMR LLC lifted its position in shares of OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of OPKO Health in the first quarter valued at $26,000. Orion Portfolio Solutions LLC acquired a new stake in OPKO Health during the 3rd quarter valued at $45,000. Finally, Algert Global LLC purchased a new stake in OPKO Health during the 2nd quarter worth $44,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on OPK. Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Tuesday, September 17th. StockNews.com raised shares of OPKO Health to a “sell” rating in a research note on Saturday, July 27th. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research report on Thursday, September 26th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research note on Friday, November 8th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.